Dr. Weber on Immunologic Activities of Targeted Agents

Jeffrey S. Weber, MD, PhD
Published: Tuesday, Nov 05, 2013

Jeffrey S. Weber, MD, PhD, medical oncologist, Department of Cutaneous Oncology, director, Donald A. Adam Comprehensive Melanoma Research Center, Moffitt Cancer Center, discusses the immunologic activities of targeted agents for the treatment of melanoma.

There has been work in the past 3-4 years suggesting that a targeted agent that should have no immunologic activity will generate an influx of immune cells into the tumor. The trick when dealing with these hidden immunologic activities of non-immune drugs is to take advantage and use them in the proper way.

Jeffrey S. Weber, MD, PhD, medical oncologist, Department of Cutaneous Oncology, director, Donald A. Adam Comprehensive Melanoma Research Center, Moffitt Cancer Center, discusses the immunologic activities of targeted agents for the treatment of melanoma.

There has been work in the past 3-4 years suggesting that a targeted agent that should have no immunologic activity will generate an influx of immune cells into the tumor. The trick when dealing with these hidden immunologic activities of non-immune drugs is to take advantage and use them in the proper way.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x